GTBIF vs MRMD: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
GTBIF is the larger of the two ($1.24B market cap): the incumbent the market prices for continued execution (21.74x forward earnings, beta 1.14). MRMD is the smaller challenger ($19.08M), still expected to post a loss next year: more room to run, but more to prove. On the numbers, GTBIF leads on both counts: faster expected revenue growth (7% vs 1%) and expected profits next year, which MRMD does not have. The case for MRMD rests on its own driver (Branded wholesale growth): if you believe in that, MRMD fits; if you believe in what the numbers show today, GTBIF does.
GTBIF vs MRMD: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GTBIF | MRMD | What it tells you |
|---|---|---|---|
| Market cap | $1.24B | $19.08M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 21.74 | -1.57 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.14 | 1.55 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 7% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.66 | 0.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how GTBIF and MRMD affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GTBIF and MRMD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GTBIF and MRMD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Green Thumb Industries (GTBIF) do?
Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. It grows, processes and sells cannabis under consumer brands such as Rythm (flower and vapes), Dogwalkers (pre-rolls), incredibles (edibles) and Beboe, and it runs roughly 100 to 115 RISE and other branded dispensaries across 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut and Nevada. Because cannabis remains federally illegal for adult use, its shares cannot list on a US exchange: they trade over the counter as GTBIF and on the Canadian Securities Exchange as GTII.
What does MariMed (MRMD) do?
MariMed Inc. is a multi-state cannabis operator headquartered in Norwood, Massachusetts. It runs cultivation and production facilities and a chain of dispensaries under the Panacea Wellness and Thrive names, with its core footprint in Massachusetts, Illinois, Maryland, Delaware and Ohio. The company is best known for its branded products rather than its stores: Betty's Eddies fruit chews, Kalm Fusion drinks and tablets, Bubby's Baked, Vibations and the Nature's Heritage flower line. Management says its brands reach about 85% of dispensaries in its core markets, and wholesale to other retailers is a growing share of sales. It has also licensed its brands into Maine and exited Missouri.
GTBIF vs MRMD: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- GTBIF drivers: Federal rescheduling and the end of 280E; New adult-use markets and store openings in its footprint.
- MRMD drivers: Branded wholesale growth; Delaware and Ohio retail expansion.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The main risk is regulatory. For MRMD, the main risk is leverage relative to a small equity value.
GTBIF or MRMD: which should you pick?
If the story you believe is GTBIF's (Federal rescheduling and the end of 280E), GTBIF is the more direct way to own it; if it is MRMD's (Branded wholesale growth), MRMD is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GTBIF and MRMD guides.
GTBIF vs MRMD: the full fundamentals
GTBIF. At ~$5.69, Green Thumb is valued at roughly 1.0 times trailing sales and about 13.5 times trailing earnings, with enterprise value under six times trailing EBITDA. The forward P/E is higher, near 22x, because consensus expects 2026 EPS of only ~$0.11 before ~$0.36 in 2027. Those multiples are low for a company with ~28% normalized EBITDA margins and positive cash flow, and the gap reflects federal illegality, 280E taxes, OTC-only trading in the US and steady price compression. The next data points are a federal rescheduling decision and the Q4 2026 report, where management has guided revenue flat to slightly down sequentially (consensus ~$323.5M).
MRMD. On equity alone MariMed looks extremely cheap, at roughly 0.11x trailing sales. That figure misleads because debt is several times the market cap. Adding ~$78.2M of mortgages and notes and subtracting ~$10.4M of cash gives an enterprise value near ~$87M, or about 0.5x sales and roughly 5x an annualized ~$19M of Q3 adjusted EBITDA. That is in the range where small cannabis operators have traded, and it excludes the large income taxes payable, which behave like additional debt. GAAP earnings are negative, so a price-to-earnings ratio is not meaningful.
Headline figures (approximate, November 2026): GTBIF shows revenue (ttm) ~$1.24B; Q3 2026 ~$324.4M, up ~11%, market cap ~$1.25B at ~$5.69 (Nov 20, 2026), price / sales ~1.0x (EV/EBITDA ~5.8x), p/e (trailing / forward) ~13.5x / ~21.9x; MRMD shows revenue (ttm) ~$167M (Q3 2026 +8.5% YoY), market cap ~$19M, share price (nov 20, 2026) ~$0.05 (YTD -48%), q3 2026 adjusted ebitda ~$4.7M (~10.5% margin).
The bottom line: GTBIF vs MRMD
GTBIF and MRMD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GTBIF and MRMD exposure against your real portfolio. It is not an investment adviser.
Wondering how GTBIF or MRMD fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Green Thumb Industries
Ask Walnut's AI anything about GTBIF and see how it fits what you own.
FAQ
What is the difference between GTBIF and MRMD?
+
Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. MariMed Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GTBIF or MRMD the better stock?
+
Neither is universally better. GTBIF is the larger incumbent; MRMD is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GTBIF or MRMD?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GTBIF and MRMD?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GTBIF vs MRMD?
+
GTBIF: The main risk is regulatory. Adult-use cannabis remains a Schedule I substance, so most of Green Thumb's sales still face Section 280E, restricted banking and no access to US stock exchanges. A broader rescheduling decision could be delayed, narrowed or challenged in court, the IRS has not issued complete guidance on how the April 2026 order applies, and management has warned that delays mean continued significant tax liabilities. Price compression is the second risk: gross margin fell roughly eight points in two years to ~45% in Q3 2026, management expects further compression in coming quarters, and new cultivation capacity in states like Illinois, New Jersey and Ohio continues to push prices down. Third, intoxicating hemp-derived THC products, now sold in mainstream retailers, compete for the same customers without cannabis licensing costs or taxes, although management said changes in hemp policy could become a tailwind. Fourth, profitability is lumpy: 2025 GAAP net income leaned on warrant fair-value gains, Q2 2026 GAAP net income was only ~$4.9M, and Q3 2026 was a GAAP net loss of ~$4.8M as SG&A rose. Consensus expects 2026 EPS of only ~$0.11 before a rebound to ~$0.36 in 2027, so the forward multiple depends on that recovery. Finally, GTBIF trades OTC with lower liquidity and higher volatility than listed stocks, many US brokers restrict cannabis names, analyst coverage on Yahoo Finance is thin (two analysts), and founder voting control limits outside shareholder influence. Growth also depends on a short list of state catalysts: Virginia adult-use is not scheduled until mid-2027, Texas timing is uncertain, and Pennsylvania and Florida have repeatedly stalled on adult-use legalization. MRMD: The main risk is leverage relative to a small equity value. Mortgages and notes payable were ~$78.2M at September 30, 2026, up from ~$72.7M at year-end 2025, against ~$10.4M of cash and quarterly adjusted EBITDA of only ~$3.6M to ~$4.7M. Covenant breaches could allow lenders to accelerate debt, as the 10-K warns. Tax is a second pressure point: large unpaid income taxes from 280E, ~$7M of disputed IRS liens and a required ~$100,000 monthly escrow tie up cash. Margins are trending down as wholesale prices fall, and a bankrupt wholesale customer already cost a write-off in 2026. The company has posted GAAP net losses (~$7.4M in the first half of 2026 and ~$3.5M more in Q3), and adjusted EBITDA margin fell to 10.5% in Q3 from 12.6% a year earlier. Federal rescheduling for adult use may be delayed or challenged. Dilution is possible through preferred stock, notes and equity raises, and a reverse split can be followed by further price declines, as often happens with OTC names. Finally, the stock is thinly traded on the OTC market, with a 52-week range of roughly ~$0.045 to ~$0.16 and a 45% decline over the three months to November 20, 2026, so quotes can move sharply on small volume.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GTBIF or MRMD; figures are approximate and dated (as of November 2026). Verify current data before investing.